Skip to main content
ENSC
NASDAQ Life Sciences

Ensysce Shareholders Approve Significant Dilution from Financing and Expanded Equity Plan

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.06
Mkt Cap
$3.85M
52W Low
$0.86
52W High
$8.969
52W Position info
23% above low
Off High info
88% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

ENSC sits 23% above its 52-week low of $0.86.

Summary

Ensysce Biosciences shareholders approved the full issuance of shares and exercise of warrants related to a prior financing, and significantly expanded the company's equity incentive plan, indicating substantial potential dilution.


Key Events · Financing and Capital Events · ENSC

  • Share and Warrant Issuance Approved

    Shareholders approved the full issuance of common stock and exercise of warrants to an investor, as required by Nasdaq Listing Rule 5635(d).

  • Equity Incentive Plan Expansion

    The 2021 Omnibus Incentive Plan was amended to increase the shares available for issuance by 600,000, from 121,457 to 721,457 shares, representing approximately 16.5% of the current market capitalization.

  • Director Elections and Auditor Ratification

    Routine proposals for the election of two Class I Directors and the ratification of Baker Tilly US, LLP as the independent accounting firm were also approved.


Analysis · ENSC · Life Sciences

The approval of the full issuance of shares and exercise of warrants to an investor, alongside a substantial increase in the equity incentive plan by 600,000 shares, signals significant potential dilution for existing shareholders. For a company with a small market capitalization, such a large increase in the share pool for compensation, representing approximately 16.5% of the current market cap, can exert considerable downward pressure on the stock price. This indicates the company's ongoing need for capital and/or reliance on equity-based compensation, which investors should monitor closely for its impact on per-share value.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ENSC was trading at $1.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $0.86 to $8.97. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ENSC - Latest Insights

ENSC
Nov 18, 2026, 5:20 PM EST
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $0.366
Real-time Price: $0.410 info
Change: +$0.044 (+12%) info
Market Cap: $7.004M info
ENSC
Nov 12, 2026, 11:18 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.380
Real-time Price: $0.410 info
Change: +$0.030 (+8%) info
Market Cap: $7.004M info
ENSC
Nov 12, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.3871
Real-time Price: $0.410 info
Change: +$0.0229 (+6%) info
Market Cap: $7.004M info
ENSC
Nov 12, 2026, 4:17 PM EST
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.3871
Real-time Price: $0.410 info
Change: +$0.0229 (+6%) info
Market Cap: $7.004M info
ENSC
Nov 12, 2026, 4:15 PM EST
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $0.3871
Real-time Price: $0.410 info
Change: +$0.0229 (+6%) info
Market Cap: $7.004M info